A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
Tuesday, July 26, 2022
Dr. Minal Barve
Tuesday, July 26, 2022
Dr. Minal Barve